Nuvation Bio reports Q2 EPS (9c), consensus (11c)

As of June 30, Nuvation Bio had cash, cash equivalents and marketable securities of $630.9M. For the three months ended June 30, research and development expenses were $18.6M, compared to $28.9M for the three months ended June 30, 2022. “We continue to enroll patients in the Phase 1 and Phase 1b studies of NUV-868 where dose escalation is ongoing. We also look forward to expanding our pipeline as we progress our first nominated DDC clinical candidate toward an IND filing, which we expect by the end of 2023. Lastly, we announced the formation of our Scientific Advisory Board, composed of leading experts in oncology drug and clinical development. We are excited to work alongside them to bring innovative new therapies to cancer patients,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.